Guidewire agreed on October 27, 2026 to acquire hyperexponential, the London-based agentic underwriting platform, for $1.7 billion in cash plus up to $400 million of contingent consideration. The shares closed that day at $169.15, down 8.05% on the announcement, against a market capitalization of $13.87 billion. Guidewire's fiscal year ends July 31, so fiscal 2027 runs to July 2027 and the close is expected in the quarter ending January 31, 2027.
Base purchase price
$1.7B
Cash at closing, inclusive of an employee retention pool; merger agreement signed Oct 27, 2026
Maximum contingent payment
up to $400M
Payable only if specified recurring-revenue targets are met after closing
New term debt
$1.0B
Term Loan A, with a binding commitment from Bank of America and Citibank; balance from cash on hand
Contribution to fiscal 2027 ARR growth
at least 650 bps
Inorganic, per the announcement; from fiscal 2028, at least 150 bps of durable organic ARR growth
Annual premium priced by hyperexponential agents
over $75B
Commercial P&C premium underwritten as of the Oct 27, 2026 announcement
Announcement-day share move
-8.05%
GWRE closed Oct 27, 2026 at $169.15, down $14.81
The price tag
What $1.7 Billion Actually Buys
Guidewire did not disclose hyperexponential's revenue, ARR, growth rate or margins. It did disclose the metric that matters: the transaction is expected to contribute at least 650 basis points to fiscal 2027 ARR growth on an inorganic basis. Back the ARR out of that sentence and the price becomes legible.
| Line | Figure | Method |
|---|---|---|
| hyperexponential ARR, implied | $80M – $95M | 6.5% of fiscal 2026 ARR of $1,237M (low end) to 6.5% of the $1,455M fiscal 2027 guide (high end) |
| Base price as a multiple of ARR | 18x – 21x | $1.7B divided by the implied ARR range |
| Full price as a multiple of ARR | 22x – 26x | $2.1B including the $400M earn-out, divided by the same range |
| Guidewire's own equity value to ARR | 9.5x – 11.2x | $13.87B market capitalization over $1,455M fiscal 2027 guided ARR and $1,237M fiscal 2026 ARR |
| Advent's price for Sapiens | about 4.6x revenue | $2.5B equity value over Sapiens' $542.4M of fiscal 2024 revenue |
| ServiceNow's price for Moveworks | about 25x ARR | $2.85B over ARR that passed $100M in late 2024 |
Two things follow. Guidewire is paying roughly twice what its own shares fetch on the same measure — 18 to 21 times ARR for hyperexponential against 9.5 to 11.2 times for Guidewire — and far more than the 4.6 times revenue that private equity paid for Sapiens, a P&C software platform with six times the revenue. And the premium is not a reward for verticality: ServiceNow paid about 25 times ARR for a general-purpose assistant. What is being rewarded is decisioning inside a locked workflow.
The growth math
The Organic Slowdown the Deal Buys Away
ARR grew 19% in constant currency in fiscal 2026, to $1,242 million. The fiscal 2027 guide of $1,450 million to $1,460 million is 18% constant-currency growth at the midpoint, and at least 650 basis points of that comes from hyperexponential rather than from new sales. Strip the acquisition out and organic ARR growth lands at roughly 11.5%, a deceleration of about 750 basis points.
Guidewire ARR: fiscal 2026 actual against the fiscal 2027 guide
The split between organic and acquired ARR is implied from the company's own 650 basis point disclosure, not reported.
Unit: USD millions
Fiscal 2026 ARR (actual)
1,237
Fiscal 2027 ARR (guided midpoint)
1,455
of which organic (implied)
1,375
of which hyperexponential (implied)
80
- Roughly 37% of the $218 million of ARR Guidewire expects to add in fiscal 2027 now arrives as an acquisition rather than as a sale, which is the single most important fact in the announcement.
- Guidewire repurchased 4.09 million shares in fiscal 2026 at an average of $148.41 for $606.3 million, and still ended the year with 31.9 million shares authorized — close to 40% of the roughly 80 million shares outstanding, worth about $5.4 billion at the Oct 27 close.
- The same $1.7 billion spent on buybacks at $169.15 would retire about 10 million shares, roughly 12% of the company, at about 11 times ARR. Buying hyperexponential does the opposite of what the buyback was doing.
- The term loan adds roughly $55 million to $65 million of pretax interest at 5.5% to 6.5%, or about $0.56 to $0.66 per diluted share after tax at the fiscal 2026 effective rate of 15.1% — a third to two-fifths of fiscal 2026 GAAP diluted EPS of $1.63.
- Pro forma net debt of about $2.0 billion is roughly 1.2 times fiscal 2027 guided revenue of $1.717 billion, against 0.22 times today, and the cash consideration equals nearly six times trailing free cash flow of $290.3 million.
Why the agent layer
The Layer Nobody Else Can Own
Everything else in the insurance AI stack is rented. Data comes from analytics vendors, actuarial modeling from pricing specialists, implementation from consultancies, and the system of record from the core platform vendor — each substitutable, each competing for the same budget. The agent that reads a submission, prices it inside appetite limits and hands it to an underwriter is the one piece a carrier cannot swap without re-underwriting its book.
We founded hyperexponential on the conviction that underwriting judgment is the highest-leverage work insurers do.
- Moody's supplies hyperexponential with entity data and analytics — name matching, enrichment and firmographics across 525 million public and private entities — and earns $8.18 billion of trailing revenue on $3.67 billion of operating income. The data layer gets paid by volume, not by the AI premium.
- Accenture runs a hyperexponential Center of Excellence with roughly 75 trained and certified professionals; Deloitte and EY have built underwriting practices trained on the hx Renew platform. The judgment that agents amplify is still largely supplied by people.
- Akur8 automates non-life premium modeling, cutting modeling time by roughly 10x and claiming 2% to 4% loss-ratio improvement potential, while CyberCube supplies cyber risk analytics. The actuarial engine is a commodity partner, not the asset.
- Duck Creek Technologies sits on the same partner directory. hyperexponential was platform-neutral, selling into carriers on Guidewire and on its direct competitor alike — and the announcement does not say whether Guidewire's ownership changes support for other core-system ecosystems.
- Swiss Re Reinsurance Solutions, Cytora, SEND, Xceedance and APR Actuarial complete the directory, while Bank of America and Citigroup supply the $1.0 billion term loan that turns the premium into a balance-sheet event.
That neutrality is the deal's real logic. On the same day it signed the merger agreement, Guidewire launched a platform where its own agents run inside the core applications and share the insurer's data and controls. Buying hyperexponential removes the last vendor-neutral orchestration layer in commercial underwriting and folds it into a system of record that already runs for more than 450 insurers. The premium is not for revenue — roughly $73 million of venture capital raised in a January 2024 Series B becomes $1.7 billion of cash — it is for the right to be the default.
Downstream economics
Who Gains Throughput, Who Loses the Premium
hyperexponential now prices underwriting decisions across more than $75 billion of annual commercial P&C premium, up from over $45 billion of gross written premium contracted through hx Renew in July 2025 — a 67% increase in fifteen months across more than 40 clients. Aviva alone runs 23 live models on the platform. Faster, more consistent pricing lifts throughput per underwriter; it also removes the patience premium that slower competitors used to enjoy.
| Customer | Financial scale | Read-through |
|---|---|---|
| Markel | $17.35B trailing revenue; $2.28B trailing net income | More submissions priced per underwriter on specialty and E&S risks; faster quotes also compress the rate premium in a softening market |
| Cincinnati Financial | $13.28B trailing revenue; $14.10 trailing diluted EPS | Pricing gains land in the commercial book's loss ratio, not in its agency distribution, so the benefit accrues slowly |
| Bowhead Specialty | $614.3M trailing revenue; $62.2B trailing net income | Throughput is the binding constraint on growth; agentic pricing loosens it without adding underwriters |
| Sompo Holdings | Tokyo-listed; named customer in the announcement | One of the few markets where agentic pricing is early enough to still be an edge, given a concentrated domestic carrier base |
| CCC Intelligent Solutions | $4.54B market capitalization; 5.2x trailing enterprise value to sales | The claims-side analogue of the underwriting agent has not been repriced the way underwriting just was |
Two adjustments to the table matter. Bowhead Specialty's trailing net income is $62.2 million, not $62.2 billion. And the read-across runs in both directions: if underwriting decisioning is worth 18 to 21 times ARR, the next repricing candidate in insurance software is claims decisioning, where CCC bought EvolutionIQ for $730 million in December 2024 — a fraction of what underwriting decisioning just commanded. At 5.2 times trailing enterprise value to sales, CCC is both a plausible acquirer of the next claims agent and a plausible target of the same trade.
Brokers see it first. If carriers put the agent to work on incoming submissions, routine risks get priced or declined before an underwriter opens the email, which shows up as a change in the broker's inbox rather than in the carrier's income statement. The open question is where responsibility for a bad decision sits, and who explains it to a judge.
Horizons
The Scoreboard: December 2026, January 2027, Fiscal 2028
- December 2026: fiscal 2027 guidance is updated at the first-quarter results call. Watch the ARR guide move from $1,455 million toward $1,535 million, gross margin — management called the deal consistent with long-term margin targets, yet hyperexponential brings roughly 300 people and a services-heavy implementation model — and the first disclosure of the recurring-revenue targets behind the $400 million earn-out.
- The quarter ending January 31, 2027: closing. Guidewire's Form 8-K states the agreement carries no closing conditions, so execution risk sits with integration and retention rather than with regulators.
- Next 12 months: the carriers named in the announcement are the ones who can show a throughput effect. If a customer using agentic pricing does not report more submissions priced per underwriter, the case for the multiple weakens from the bottom up.
- Fiscal 2028 is the real test. Management promises at least 150 basis points of durable organic ARR acceleration from fiscal 2028. Organic ARR growth of roughly 13% or better means the deal worked at the growth line; 11.5% means Guidewire paid 18 to 21 times ARR for a deceleration it already had.
- Commoditization is the structural bear case. If general-purpose models plus a carrier's own data reach the same pricing quality, the orchestration layer stops being scarce and the multiple has nowhere left to go.
- Concentration cuts both ways. Allianz, Sompo, Aviva and HDI sit inside the customer list, so a single large carrier re-tendering its pricing would hit the recurring-revenue targets that unlock the earn-out.
- Leverage is the balance-sheet risk. About $2.0 billion of pro forma net debt and roughly $60 million of new pretax interest land on a business that earned $150.3 million of trailing GAAP operating income, with free cash flow of $290.3 million already consumed by the buyback.
Where the agent premium shows up in listed stocks
- hyperexponential costs roughly 18 to 21 times ARR against Guidewire's own 9.5 to 11.2 times, so the acquirer is paying about twice its own multiple for bought growth.
- Shares fell 8.05% to $169.15 on the announcement; investors are discounting the quality of the growth rather than the AI.
- Organic ARR growth drops from 19% in fiscal 2026 to roughly 11.5% in fiscal 2027 once the 650 basis point inorganic contribution is removed.
- The $1.0 billion term loan adds $55 million to $65 million of pretax interest, a third to two-fifths of fiscal 2026 GAAP operating income of $150.3 million.
- December 2026 is the checkpoint: updated fiscal 2027 ARR guidance should land near $1,535 million if hyperexponential closes on schedule.
- hyperexponential's pricing agents lift submission throughput per underwriter, the binding constraint on Markel's specialty growth.
- Trailing revenue of $17.35 billion and trailing net income of $2.28 billion give Markel scale to absorb a much faster quote cycle.
- The offset: faster AI-assisted quoting compresses the rate premium specialty carriers earn from slow, human-paced underwriting.
- Horizon: 12 months, visible in quote turnaround and submission counts rather than in reported margins.
- Cincinnati Financial is named among hyperexponential's customers, so parts of its $13.28 billion of trailing revenue are already priced by agentic models.
- Trailing diluted EPS of $14.10 means the benefit lands in the commercial book's loss ratio, not in its agency distribution.
- The offset: Cincinnati has been building its own AI tooling and can duplicate much of the gain without buying a platform.
- Horizon: 12 to 24 months; December 2026 guidance updates tell the market about Guidewire, not about carriers.
- Bowhead's growth is bounded by underwriting capacity, and agentic pricing raises the premium each underwriter can write without adding headcount.
- Trailing revenue of $614.3 million and trailing net income of $62.2 million sit on a book that must grow into fixed cost.
- Bowhead is named in the acquisition announcement, so the deployment is live rather than a pilot.
- Horizon: 12 months; if premium growth stalls despite the tooling, the capacity thesis is wrong.
- CCC paid $730 million for EvolutionIQ in December 2024, a fraction of the 18 to 21 times ARR underwriting decisioning just commanded.
- At 5.2 times trailing enterprise value to sales and 3.9 times net debt to EBITDA, CCC is the cheapest listed way to own claims decisioning.
- The risk: auto-claims concentration leaves CCC outside the underwriting workflow where the agent premium is being discovered.
- Horizon: 12 to 36 months; the trigger is a claims-AI acquisition or a takeout.
- Every agentic submission multiplies lookups, and Moody's supplies name matching and firmographics across 525 million entities to hyperexponential.
- Moody's earns $8.18 billion of trailing revenue and $3.67 billion of operating income, paid by data volume rather than by the AI premium.
- hyperexponential's premium underwritten grew from $45 billion to $75 billion in fifteen months, dragging data consumption with it.
- Horizon: fiscal 2027 to 2028, as agentic submission volume compounds.
- Sompo is one of the named hyperexponential customers, so agentic pricing already sits inside a Tokyo-listed balance sheet.
- Guidewire's entire APAC revenue was $114.7 million in fiscal 2026, so Japan matters more to the carrier than to the vendor.
- The offset: Japan's commercial insurance market is concentrated, so an early agentic edge erodes as peers deploy the same tooling.
- Horizon: fiscal 2027 to 2028; watch underwriting productivity rather than premium growth.
